SecBot SecBot
8-K ·Filed May 7, 2026

VTRS

Viatris Inc
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001792044-26-000025
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong Q1 beat and reaffirmed guidance reinforce the narrative of operational improvement and cost savings from the enterprise-wide strategic review. Traders should watch upcoming PDUFA dates (MR-141 for presbyopia in October, low-dose estrogen patch in July) and the March 2026 Investor Event for long-term targets.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$17.39
T+0 close · May 7, 2026 · via day close
Latest settled
+1.38%
T+60 · $17.63
Vs SPY
−2.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $17.39entry
  2. T+1 · 6mo ago −1.27%α −2.10% · $17.17
  3. T+5 · 6mo ago −0.12%α −1.62% · $17.37
  4. T+20 · 6mo ago −10.52%α −13.66% · $15.56
  5. T+60 · 4mo ago +1.38%α −2.45% · $17.63

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Viatris reported Q1 2026 adjusted EPS of $0.59, 18% above consensus of $0.50, and revenue of $3.52B, 5% above consensus of $3.36B. Results were driven by strong growth in Greater China and brands, with adjusted EBITDA up 10% operationally. The company reaffirmed its 2026 guidance, signaling confidence in its turnaround and cost-savings plan.

Key Financial Metrics

EPS
$0.59
est $0.50 · +18.0%
Revenue
$3.5B
est $3.4B · +4.7% · +8.1% YoY
Rating
strong beat
Guidance
$14,450M - $14,950M
maintained
Free Cash Flow
$348.4M
Gross Margin
32.9%

Key Facts

  • Q1 2026 total revenues of $3.517B, up 8% reported (3% operational) YoY
  • Adjusted EPS of $0.59 vs consensus $0.50 (18% beat); GAAP EPS $0.15
  • Adjusted EBITDA of $1.05B, up 14% reported (10% operational) YoY
  • Reaffirmed 2026 guidance: revenue $14.45-14.95B, adjusted EBITDA $4.15-4.45B, adjusted EPS $2.33-2.47
  • Greater China net sales up 22% reported (18% operational)
  • Fire at Nashik facility caused $71.9M write-off in Q1; expects to resume operations in April 2026

Financial Impact

Adjusted EPS beat by 18% ($0.59 vs $0.50); revenue beat by 5% ($3.517B vs $3.36B); guidance reaffirmed

revenueepsadjusted_ebitda

Risk Factors

  • Restructuring and fire-related costs could weigh on GAAP profitability
  • Generic competition and pricing pressure in developed markets
  • Execution risk on $700-850M restructuring program

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001792044-26-000025
Document: vtrs-20260507.htm0001792044-26-000025
Document: 0001792044-26-000025-index-headers.html0001792044-26-000025
Document: 0001792044-26-000025-index.html0001792044-26-000025
Document: 0001792044-26-000025.txt0001792044-26-000025
8-K Data (Synthetic)0001792044-26-000025

US Market Status

Market Open · Closes in 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026